The assistant professor at Cleveland Clinic discussed findings from a recently published study that provided insights on the understanding of the molecular basis for female predominance in Alzheimer disease. [WATCH TIME: 3 minutes]
AUPN Leading Edge Episode 4 features Rohit Das, MD, and Joseph R. Berger, MD, who discuss how neurologists are undervalued in academic and non-academic settings when their compensation is predicated on RVUs alone. [LISTEN TIME: 26 minutes]
The Cleveland Clinic researcher discussed the unknowns about Parkinson disease dementia and what has been previously observed in clinical studies.
The duo from the Critical Path Institute detailed the thought process behind evaluating the importance of specific biomarkers and their relation to disability progression in Alzheimer disease.
The nurse practitioner in the movement disorder division at Georgetown University Hospital discussed differences in available therapies for movement disorders versus multiple sclerosis and using a chronic care management model in Parkinson disease. [WATCH TIME: 5 minutes]
The associate professor of neurosurgery at Robert Wood Johnson Medical School talked about minimally invasive techniques and neurostimulation strategies to make epilepsy surgery safer and more effective. [WATCH TIME: 7 minutes]
Expert neurologists share approaches to switching MG treatment due to either poor disease control or adverse events.
The associate professor at Yeshiva University and Albert Einstein College of Medicine explored the challenge of discussing lifestyle changes for patients with migraine, noting that lifestyle modifications can be a valuable addition to migraine treatment. [WATCH TIME: 3 minutes]
The graduate student at the University of Michigan provided insight on her study examining longitudinal patterns of difficulty initiating sleep and their associations with subsequent memory trajectories among different races and genders. [WATCH TIME: 3 minutes]
Many programs and activities at the 2023 CMSC Annual Meeting focused on burnout prevention and supporting the current and future MS care workforce.
Expert neurologists provide insight on unmet needs, challenges to improve access to care, and highlight clinical pearls for the management of OFF episodes in Parkinson disease.
The professor of neurology, psychiatry, and pharmacology at the NYU Grossman School of Medicine commented on the differences in mechanisms and clinical trial data between lecanemab and donanemab. [WATCH TIME: 5 minutes]
At the 2023 MDA Conference, a neurology nurse practitioner in the Neuromuscular Division at Washington University in St. Louis talked about adverse event management of gene therapies in Duchenne muscular dystrophy. [WATCH TIME: 2 minutes]
The postdoctoral researcher at Columbia University discussed the long-term plans to gain a better understanding of MS diagnosis disclosure and how it can impact other qualities of life.
The associate professor of neurology at Albert Einstein College of Medicine talked about a review on neonatal seizures recently published in the New England Journal of Medicine. [WATCH TIME: 5 minutes]
Joseph R. Berger, MD, and Fred D. Lublin, MD, offer advice to community physicians and neurologists in managing patients with multiple sclerosis.
A pair of cerebrovascular and neurosurgery experts discuss a novel approach to communicating hydrocephalus with an arachnoid granulation using a miniature implant, delivered via a percutaneous endovascular catheter.
The neurosurgeon at Marcus Neuroscience Institute, Baptist Health, provided perspective on the advances of DBS and other invasive procedures for patients with degenerative disorders. [WATCH TIME: 4 minutes]
The adjunct professor of human genetics at Emory University School of Medicine discussed previous research on Rett syndrome that initially provided crucial insight on the neuromuscular condition in adult populations. [WATCH TIME: 2 minutes]
The professor of neurology at Brigham and Women’s Hospital discussed her presentation on B-cell depleting therapies such as ocrelizumab and ofatumumab for the treatment of multiple sclerosis. [WATCH TIME: 2 minutes]
Despite years of use of gold-standard therapy levodopa, therapeutic development in Parkinson disease has advanced rapidly and expanded to numerous novel pathways and targets.
The professor of neurology and biostatistician at University of Melbourne and Royal Melbourne Hospital spoke on stem cell transplantation in patients with MS and its effectiveness in comparison with other traditional approaches. [WATCH TIME: 2 minutes]
The professor of clinical neurology at University of Miami and MT2020+ chair, and president of Medtronic's Neurovascular Business discussed the effort to improve global accessibility of mechanical thrombectomy.
The vice chair for research at the Northwestern University Feinberg School of Medicine discussed the potential of the mobile toolbox battery to screen hundreds of thousands for cognitive impairment.
Magnetoencephalography provides an opportunity for physicians to capture a more dynamic view of brain function over time and space that may offer an advantage to clinical care.
Falls cost the US more than $50 billion annually, but platforms like CatchU, a transformative digital health tool, provide quantitative fall assessment that might significantly enhance the current standard of care for predicting falls.
Episode 36 of the AUPN Leadership Minute features Rohit Das, MD, of University of Texas Southwestern Medical Center at Dallas; and David G. Standaert, MD, PhD, of the University of Alabama at Birmingham. [WATCH TIME: 4 minutes]
The journey of aducanumab (Aduhelm; Biogen) from development to the FDA is a tortured one, but its path may serve to teach the Alzheimer disease field valuable lessons as it strives forward to develop disease-modifying therapies.
The director and founder of The MS Center for Innovations in Care provided thoughts on the potential role of biosimilars in treating multiple sclerosis and the steps needed to ensure that this integration process is safe. [WATCH TIME: 4 minutes]
Surgical care for PD is safe and effective, and should no longer be treated as a consideration of last resort, but as a treatment option discussed early in the disease course with the patient and their family.